Laser treatment for fistulas in hidradenitis suppurativa
Intralesional Diode Laser Treatment of Fistulas in Hidradenitis Suppurativa: Protocol for a Within-person Randomised Trial
This study is testing a new laser treatment for people with hidradenitis suppurativa who have fistulas to see if it helps them heal and feel better.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 20 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Zealand University Hospital Academic / other |
| Locations | 1 site (Roskilde) |
| Trial ID | NCT04508374 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the use of 1470 nm intra-lesional diode laser treatment for patients suffering from hidradenitis suppurativa (HS) with two appropriate fistulas. The study aims to evaluate the effectiveness of this novel laser technique in promoting healing and alleviating symptoms associated with HS. Participants will receive laser treatment on both the right and left HS tunnels, with the goal of reducing pain and improving quality of life. The approach is based on emerging evidence suggesting that laser therapy may provide a less invasive alternative to traditional surgical interventions.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 years or older with two appropriate HS fistulas.
Not a fit: Patients with fistulas in areas that have previously undergone surgery or those with fragile health may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could significantly improve healing rates and quality of life for patients with hidradenitis suppurativa.
How similar studies have performed: Previous studies on laser treatment for perianal fistulas have shown promising results, indicating potential success for this approach in HS.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Legally competent women and men * aged 18 years or older * Two appropriate HS fistulas Exclusion Criteria: * fistulas in areas that have previously received surgery * Allergy to lidocaine or adrenaline * Fragile physical health that cannot tolerate standard of care HS rescue therapy * Pregnant or lactating women
Where this trial is running
Roskilde
- zealand University Hospital Roskilde — Roskilde, Denmark (Recruiting)
Study contacts
- Principal investigator: Gregor BE Jemec, DmSc, Prof. — Zealand University Hospital - Roskilde
- Study coordinator: Gregor BE Jemec, Prof., DmSc
- Email: gbj@regionsjaelland.dk
- Phone: +4547322600
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.